Parhelia Biosciences

Parhelia Biosciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Parhelia Biosciences is a private, commercial-stage company providing an integral automation solution for spatial biology workflows. Founded in 2018 and based in San Diego, the company addresses critical pain points in spatial biology labs—including manual labor, assay variability, and reagent waste—with its Spatial Station instrument and Skylab reagent kits. Its technology is chemistry-agnostic and supports a wide range of applications from dewaxing and antigen retrieval to panel mixing for high-plex protein and RNA assays, positioning it as a workflow enabler for the rapidly growing spatial biology market.

Oncology

Technology Platform

The Spatial Station: a benchtop instrument automating spatial biology sample prep via uniform capillary gap staining, precision temperature control (0-100°C), automated panel mixing, and chemistry-agnostic protocol execution. Supported by Skylab reagent kits and an intuitive touchscreen interface for protocol building.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The spatial biology market is experiencing rapid growth, creating a strong demand for solutions that automate complex, manual sample preparation to improve reproducibility and throughput.
Parhelia's chemistry-agnostic platform allows it to serve a wide range of existing and emerging high-plex assays, making it a versatile hub for the lab.
Strategic partnerships with leading spatial technology providers (e.g., Akoya for PCF) can drive bundled sales and establish its instrument as a standard.

Risk Factors

Market adoption may be slowed by the capital cost of the instrument and the need for labs to change established manual protocols.
The company faces potential competition from larger, well-funded life science tools companies that could develop similar automation solutions.
As a young hardware company, execution risks in manufacturing, global support, and scaling operations are significant.

Competitive Landscape

Direct competition in the niche of integrated automation for high-plex spatial biology is currently limited. Parhelia competes against manual processes and standalone pieces of equipment (e.g., water baths, manual slide stainers). Broader competition comes from companies offering automated IHC stainers (e.g., Roche Ventana, Leica, Agilent), but these are often optimized for lower-plex clinical workflows and may not support the complex, multi-cycle protocols required for assays like CODEX/PCF.